Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis

Inclusion Criteria:

* Female patients 18 years old and above.
* Histology confirmed unilateral breast cancer following lumpectomy
* Planned to receive 50 Gy, whole breast XRT and regional lymph nodes radiation.
* ECOG performance status 0-2
* Completed Chemotherapy 3 weeks prior to XRT (if applicable)
* Patient should be available for the entire study period, and be able and willing to adhere to protocol requirements;
* Patient must sign an informed consent form prior to undergoing any study-related procedures

Exclusion Criteria:

* Known uncontrolled diabetes
* Prior radiation to breast
* Known connective tissue disorder
* Known skin disease over the treated breast
* Prior burn over treated area
* Evidence of infection or inflammation of breast to be treated.
* Receiving biological therapy or hormone therapy (other than Herceptin) during radiation treatment/study duration and 4 weeks prior to study entry.
* Pre-existing skin breakdown within the planned radiotherapy field at the time of study entry.
* Pregnancy, planned pregnancy, lactation or inadequate contraception as judged by the Investigator.
* Participation in another investigational drug or vaccine trial concurrently or within 30 days.
* Use of any other topical or systemic treatments aimed at radiation dermatitis.
* Use of a prescription or over-the-counter medication that contains hydrocortisone or any other cortisone or corticosteroid containing preparation